Background: Oncogene HCCR-1 functions as a negative regulator of the p53 and contributes to tumorigenesis of various human tissues. However, it is unknown how HCCR-1 contributes to the cellular and biochemical mechanisms of human tumorigenesis.
Results: In this study, we showed how the expression of HCCR-1 is modulated. The luciferase activity assay indicated that the HCCR-1 5'-flanking region at positions -166 to +30 plays an important role in HCCR-1 promoter activity. Computational analysis of this region identified two consensus sequences for the T-cell factor (TCF) located at -26 to -4 (Tcf1) and -136 to -114 (Tcf2). Mutation at the Tcf1 site led to a dramatic decrease in promoter activity. Mobility shift assays (EMSA) revealed that nuclear proteins bind to the Tcf1 site, but not to the Tcf2 site. LiCl, Wnt signal activator by GSK-3beta inhibition, significantly increased reporter activities in wild-type Tcf1-containing constructs, but were without effect in mutant Tcf1-containing constructs in HEK/293 cells. In addition, endogenous HCCR-1 expression was also increased by treatment with GSK-3beta inhibitor, LiCl or AR-A014418 in HEK/293 and K562 cells. Finally, we also observed that the transcription factor, TCF, and its cofactor, beta-catenin, bound to the Tcf1 site.
Conclusion: These findings suggest that the Tcf1 site on the HCCR-1 promoter is a major element regulating HCCR-1 expression and abnormal stimulation of this site may induce various human cancers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693525 | PMC |
| http://dx.doi.org/10.1186/1471-2199-10-42 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TCF1 dosage determines cell fate during T cell development.
Sci Adv
November 2024
Laboratory of Clinical Investigation, National Institute on Aging, Baltimore, MD, USA.
Article Synopsis
- - Loss-of-function studies reveal that T cell factor-1 (TCF1) is crucial for T cell development in the thymus, and its expression is regulated by E box DNA binding proteins independently of Notch signaling.
- - Systematic analysis of five E protein binding elements (EPE1-5) shows that EPE3 is vital for αβ T cell development, while EPE1, 3, and 5 are important for γδ T cell maturation and fate decisions.
- - The balanced expression of TCF1, influenced by specific EPEs, is essential for generating the appropriate number of T cells in the thymus.
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade.
J Immunother Cancer
August 2024
Philochem AG, Otelfingen, Switzerland
Article Synopsis
- Anti-PD-1 antibodies have transformed cancer treatment by achieving lasting remission in some patients, leading researchers to seek ways to enhance their effectiveness with new biomarkers and drugs.
- This study introduces F8(scDb)-IL7, a novel fusion protein targeting EDA-FN, which is present in most tumors but rare in healthy tissue, potentially improving cancer therapy at the disease site.
- F8(scDb)-IL7 was shown to boost T Cell Factor 1 expression in CD8+T cells and effectively eradicates sarcoma lesions when used alongside anti-PD-1 treatment, suggesting a promising combination for cancer patients.
PGE limits effector expansion of tumour-infiltrating stem-like CD8 T cells.
Nature
May 2024
Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Cancer-specific TCF1 stem-like CD8 T cells can drive protective anticancer immunity through expansion and effector cell differentiation; however, this response is dysfunctional in tumours. Current cancer immunotherapies can promote anticancer responses through TCF1 stem-like CD8 T cells in some but not all patients. This variation points towards currently ill-defined mechanisms that limit TCF1CD8 T cell-mediated anticancer immunity.
View Article and Find Full Text PDFHypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models.
Theranostics
April 2024
Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Hypofractionated radiotherapy (hRT) can induce a T cell-mediated abscopal effect on non-irradiated tumor lesions, especially in combination with immune checkpoint blockade (ICB). However, clinically, this effect is still rare, and ICB-mediated adverse events are common. Lenalidomide (lena) is an anti-angiogenic and immunomodulatory drug used in the treatment of hematologic malignancies.
View Article and Find Full Text PDFActivation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8 T cell exhaustion.
Nat Immunol
October 2023
Department of Oncology, UNIL CHUV, University of Lausanne, Lausanne, Switzerland.
Persistent exposure to antigen during chronic infection or cancer renders T cells dysfunctional. The molecular mechanisms regulating this state of exhaustion are thought to be common in infection and cancer, despite obvious differences in their microenvironments. Here we found that NFAT5, an NFAT family transcription factor that lacks an AP-1 docking site, was highly expressed in exhausted CD8 T cells in the context of chronic infections and tumors but was selectively required in tumor-induced CD8 T cell exhaustion.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!